May 2025– date –
-
Oncology Drug Approval News Flash: Retifanlimab-dlwr (Zynyz) Approved by FDA for Squamous Cell Carcinoma of the Anal Canal
【FDA Approval Alert】Incyte's retifanlimab-dlwr (Zynyz) Approved for Squamous Cell Carcinoma of the Anal Canal (May 15, 2025) On May 15, 2025, the U.S. FDA approved retifanlimab-dlwr (Zynyz) for adults with inoperable locally recurrent ... -
Oncology Drug Approval News Flash: Telisotuzumab Vedotin-tllv (Emrelis) Receives Accelerated FDA Approval for High c-Met NSCLC
【FDA Approval Alert】AbbVie's telisotuzumab vedotin-tllv (Emrelis) Accelerated Approval for High c-Met Non-Small Cell Lung Cancer (May 14, 2025) On May 14, 2025, the U.S. FDA granted accelerated approval to telisotuzumab vedotin-tllv (E... -
Oncology Drug Approval News Flash: Belzutifan (Welireg) Approved by FDA for Pheochromocytoma and Paraganglioma
【FDA Approval Alert】Merck's belzutifan (Welireg) Approved for Pheochromocytoma and Paraganglioma (May 14, 2025) On May 14, 2025, the U.S. FDA approved belzutifan (Welireg) for patients aged 12 years and older with locally advanced, unr... -
Oncology Drug Approval News Flash: Avutometinib + Defactinib (Avmapki Fakzynja Co-pack) Receives Accelerated FDA Approval for KRAS-Mutated LGSOC
【FDA Approval Alert】Verastem's avutometinib + defactinib Approved for KRAS-Mutated Low-Grade Serous Ovarian Cancer (May 8, 2025) On May 8, 2025, the U.S. FDA granted accelerated approval to avutometinib + defactinib (Avmapki Fakzynja C...
1